Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression

Major Depressive Disorder Clinical Trial

Official title:

Sex, Hormones and GABA in Stress Induced Anhedonia in Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03031665
• Other study ID #: 2016P000693
• Status: Completed
• Start date: October 1, 2017
• Est. completion date: June 15, 2022

Study information

• Verified date: March 2024
• Source: Mclean Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Using an innovative multi-modal imaging approach, this study investigates the role of the neurochemical gamma-aminobutyric acid (GABA), brain activity, as well as hormones in understanding sex differences in Major Depressive Disorder (MDD). Further, the investigators will link these markers to symptoms of depression.

Description:

The goals of this research are to investigate: (1) functional and neurochemical features associated with depression irrespective of clinical state; (2) moderating effects of hormones on stress circuitry in MDD; and (3) sex differences in symptoms. To this end, the study is enrolling adults with current depression and remitted depression, along with a control group of psychiatrically health adults. Participants will have an magnetic resonance imaging (MRI) exam involving multiple imaging techniques (functional, structural, spectroscopic) while performing computer-based tests. Additional questionnaires and tests will be done outside the scanner to assess current symptoms and hormone levels. The integration of laboratory-based measures of reward and stress sensitivity, with state-of-the-art imaging techniques and hormonal assessments promises to provide novel insights in the sex-dependent manifestation and pathophysiology of MDD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 251
• Est. completion date: June 15, 2022
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 25 Years

Eligibility

Inclusion Criteria for all participants.

• Males and females aged 18 through 25
• Capable of providing written informed consent, and fluent in English
• Right-handed
• Absence of any psychotropic medications for at least 2 weeks
• Female subjects will be scheduled to participate during the follicular phase of their menstrual cycle

Inclusion Criteria for "Current MDD" group:

• Meets inclusion criteria for all subjects, plus:
• Meets diagnostic criteria for a current episode of Major Depressive Disorder (MDD), as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Inclusion Criteria for "Remitted MDD" group:

• Meets inclusion criteria for all subjects, plus:
• History of MDD as defined by DSM-5, but in remission for the past two months
• Absence of anxiety disorder for the past two months

Exclusion Criteria for all participants:

• History of psychiatric illnesses, other than depression or anxiety disorders among the Current MDD and Remitted MDD groups.
• History of psychotic episodes, suicidal ideation, or of electroconvulsive therapy (ECT) treatment
• Use of hormone replacement therapy, or of anabolic steroids.
• Use of hormonal contraceptives is permitted for female subjects only if the subject has regular menses
• Failure to meet any MRI safety requirements
• Serious or unstable medical illness, or history of neurological disease or damage
• History of use of cocaine, stimulants, or dopaminergic drugs
• History of substance use disorder or alcohol use disorder (as these terms are defined by DSM-5); except depressed subjects may have a history of 'Mild' substance/alcohol use disorder only if it ended as least 12 months ago.

Related Conditions & MeSH terms

• Anhedonia
• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Locations

Country	Name	City	State
United States	McLean Hospital	Belmont	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Mclean Hospital	Brigham and Women's Hospital, Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood oxygen level-dependent (BOLD) activation in response to stress	Region-specific BOLD activation in response to stress in hypothalamus, amygdala, medial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, and hippocampus	Baseline.
Secondary	Network-specific effective connectivity	Region-specific resting state connectivity of two networks (1) hypothalamus and amygdala, with medial prefrontal cortex and orbitofrontal cortex; and (2) hypothalamus and amygdala, with hippocampus	Baseline
Secondary	GABA concentration	Region-specific GABA concentration measured in rostral anterior cingulate cortex and dorsolateral prefrontal cortex	Baseline